Skip to main content
. 2009 Aug;12(4):259–267. doi: 10.1089/rej.2009.0854

FIG. 4.

FIG. 4.

Effect of Ndi1 treatment on striatal dopaminergic proteins and Ndi1 in the chronic parkinsonian mice. The expression of several dopaminergic functional proteins was analyzed in each side of neostriatum from control (N = 8) and chronic MPTP/probenecid-treated mice 5 weeks after treatment, which had been pretreated without (N = 6) or with (N = 8) NDI1 gene for 8 months. The protein expression of VMAT2, DAT, and TH on the left (LH) and right hemispheres (RH) in the chronic parkinsonian mice 5 weeks after systemic injections with MPTP/probenecid was markedly reduced (a and b). Marked Ndi1 expression could be detected in the injected side of the striatum from the chronic parkinsonian mice pretreated with NDI1 (a and b). Sustained expression of VMAT2, DAT, and TH proteins was observed in the right striatum of the chronic parkinsonian mice, which had been pretreated ipsilaterally with rAAV-NDI1 8 months the chronic MPTP/probenecid treatment (a and b). Results are expressed as mean ± SEM. ***p 0.001; **p < 0.01; *p < 0.05. MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; VMAT2, vesicular monoamine transporter 2; DAT, dopamine transporter; TH, tyrosine hydroxylase; SEM, standard error of the mean; Prob., probenecid.